Form 4: CONMED Corp: Director Mark Kaye Acquires Shares

CONMED Corp director Mark Kaye reported the acquisition of 668 Restricted Stock Units (RSUs) and the vesting of 5,772 RSUs on June 2, 2026.

Summary

• Director Mark Kaye acquired 668 Restricted Stock Units (RSUs) on June 2, 2026.
• These RSUs represent a contingent right to receive one share of CONMED Corporation common stock.
• The RSUs are subject to the terms of the Company's 2025 Long-Term Incentive Plan.
• The acquired RSUs generally vest 100% after a one-year period.
• Additionally, 5,772 RSUs vested on June 1, 2026, with a contingent right to receive common stock.
• These vested RSUs are also subject to the 2025 Long-Term Incentive Plan and vest after one year.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents routine insider transactions related to compensation and does not inherently signal a change in the company's fundamental performance or outlook.

Positives

• Director Mark Kaye's acquisition of RSUs indicates continued confidence and investment in the company.
• The vesting of 5,772 RSUs suggests that performance or tenure-based vesting conditions have been met.
• The transactions are part of the company's Long-Term Incentive Plan, aligning executive interests with long-term shareholder value.

Future Outlook

The RSUs acquired and vested are subject to vesting schedules, with the earliest potential vesting for the 5,772 RSUs on June 1, 2027, and the 668 RSUs on June 2, 2026. The expiration dates are June 1, 2036, and June 2, 2035, respectively.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The acquisition and vesting of Restricted Stock Units (RSUs) by a director like Mark Kaye are common practices in the medical technology industry to incentivize and retain key leadership, aligning their interests with long-term company performance.

Stakeholder Impact

• Shareholders: The transactions reflect standard executive compensation practices and do not immediately impact share price, but signal director commitment.
• Employees: The Long-Term Incentive Plan, under which these RSUs are granted, is a common tool for employee motivation and retention.
• Management: The transactions are part of Mark Kaye's compensation as a director.

Next Steps

• Vesting of 668 RSUs on June 2, 2026.
• Vesting of 5,772 RSUs on June 1, 2027.

Key Dates

Keywords

CONMED Corp, CNMD, Form 4, Insider Trading, Restricted Stock Units, RSUs, Director, Beneficial Ownership, Securities Exchange Act